ImmuPharma plc (LON:IMM – Get Free Report) fell 15.6% during mid-day trading on Wednesday . The stock traded as low as GBX 4.60 ($0.06) and last traded at GBX 4.98 ($0.06). 68,204,375 shares were traded during mid-day trading, an increase of 164% from the average session volume of 25,820,418 shares. The stock had previously closed at GBX 5.90 ($0.07).
ImmuPharma Stock Performance
The firm has a market capitalization of £20.74 million, a P/E ratio of -498.00 and a beta of 1.53. The firm has a 50 day moving average price of GBX 1.92 and a two-hundred day moving average price of GBX 1.78.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- NYSE Stocks Give Investors a Variety of Quality Options
- 3 Steel Stocks Soaring After Tariff Announcements
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Why Salesforce Stock Could Be at Fresh Highs by February
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
